Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 1996;27:2282-2286

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sharkey, J.
Right arrow Articles by Hayes, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sharkey, J.
Right arrow Articles by Hayes, R. L.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Movement Disorders

(Stroke. 1996;27:2282-2286.)
© 1996 American Heart Association, Inc.


Articles

Tacrolimus (FK506) Ameliorates Skilled Motor Deficits Produced by Middle Cerebral Artery Occlusion in Rats

John Sharkey, PhD; Jane H. Crawford, BSc; Steven P. Butcher, PhD Hugh M. Marston, PhD

the Fujisawa Institute of Neuroscience (J.S., S.P.B., H.M.M.) and the Department of Pharmacology (J.H.C.), University of Edinburgh (UK).

Correspondence to Dr John Sharkey, Fujisawa Institute of Neuroscience, University of Edinburgh, Appleton Tower, Level 6, Crichton St, Edinburgh, EH8 9LE, UK. E-mail j.sharkey@ed.ac.uk.

Background and Purpose Tacrolimus (FK506) is a potent immunosuppressant that is presently in clinical use for prevention of allograft rejection. Recently, animal studies reporting significant reductions in the volume of tissue damage associated with cardiac, hepatic, and cerebral ischemia suggest that tacrolimus may also be of use in the clinical management of stroke. In the present study, we examine whether the neuroprotective effects of tacrolimus, as assessed by histological outcome, are accompanied by an amelioration of the skilled motor deficits induced in the rat by middle cerebral artery occlusion (MCAO).

Methods Animals were trained to perform a skilled paw-reaching task before MCAO by perivascular microinjections of endothelin-1. Tacrolimus (1 mg/kg, n=6) or vehicle (n=6) was administered by intravenous infusion 1 minute after MCAO. After a 5-day postoperative recovery period, the rats were retested for skilled paw-reaching ability for an additional 9 days.

Results In vehicle-treated rats, MCAO resulted in a profound bilateral impairment in skilled paw use. Rats treated with tacrolimus, although still impaired, performed significantly better than those treated with vehicle alone (P<.01). Histological analysis, 14 days after occlusion, confirmed the neuroprotective efficacy of tacrolimus with a 66% reduction in the volume of hemispheric brain damage produced by MCAO (P<.01).

Conclusions The present studies show that tacrolimus not only protects neural tissue from focal cerebral ischemia but also significantly ameliorates the deficits in skilled motor ability produced by this lesion. These data provide further support for the view that tacrolimus may be of use in the treatment of stroke.

Editorial Comment

Ronald L. Hayes, PhD, Guest Editor

Department of Neurosurgery Research Labs, University of Texas Health Science Center, Houston, Tex




This article has been cited by other articles:


Home page
J. Neurosci.Home page
G. F. Hedou, K. Koshibu, M. Farinelli, E. Kilic, C. E. Gee, U. Kilic, K. Baumgartel, D. M. Hermann, and I. M. Mansuy
Protein Phosphatase 1-Dependent Bidirectional Synaptic Plasticity Controls Ischemic Recovery in the Adult Brain
J. Neurosci., January 2, 2008; 28(1): 154 - 162.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
H. Takamatsu, H. Tsukada, A. Noda, T. Kakiuchi, S. Nishiyama, S. Nishimura, and K. Umemura
FK506 Attenuates Early Ischemic Neuronal Death in a Monkey Model of Stroke
J. Nucl. Med., December 1, 2001; 42(12): 1833 - 1840.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
T. J. Toung, A. Bhardwaj, V. L. Dawson, T. M. Dawson, R. J. Traystman, P. D. Hurn, and P. H. Chan
Neuroprotective FK506 Does Not Alter In Vivo Nitric Oxide Production During Ischemia and Early Reperfusion in Rats • Editorial Comment
Stroke, June 1, 1999; 30(6): 1279 - 1285.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. Bochelen, M. Rudin, and A. Sauter
Calcineurin Inhibitors FK506 and SDZ ASM 981 Alleviate the Outcome of Focal Cerebral Ischemic/Reperfusion Injury
J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 653 - 659.
[Abstract] [Full Text]


Home page
StrokeHome page
A. Tsujikawa, Y. Ogura, N. Hiroshiba, K. Miyamoto, J. Kiryu, Y. Honda, and V. L. Dawson
Tacrolimus (FK506) Attenuates Leukocyte Accumulation After Transient Retinal Ischemia • Editorial Comment
Stroke, July 1, 1998; 29(7): 1431 - 1438.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
D. C. Rogers, C. A. Campbell, J. L. Stretton, and K. B. Mackay
Correlation Between Motor Impairment and Infarct Volume After Permanent and Transient Middle Cerebral Artery Occlusion in the Rat
Stroke, October 1, 1997; 28(10): 2060 - 2066.
[Abstract] [Full Text]